Intercell's investigational vaccine enhancement patch system for avian H5N1 influenza has failed a Phase II study. The company is working under a contract with Human and Health services (HHS) to develop a dose-sparing approach with potential for a single dose immunization combining a H5N1 vaccine with Intercell's LT adjuvant patch.
The mid-stage study was designed to determine the safety and the optimal combination/dose of an injectable H5N1 influenza vaccine and Intercell's visually evoked potential (VEP) applied at the injection site. A total of 500 healthy adults were recruited in six study groups. However, the study failed to identify the optimal combination because no statistically significant difference in seroprotection rates was observed when comparing groups with and without VEP, according to an Intercell release.
Intercell intends further evaluate its VEP in combination with an injectable H5N1 vaccine to be supplied by GlaxoSmithKline, according to a company statement. HHS and Intercell are currently considering the next steps for this development program.
The company's stock was trading 4.1 percent lower after earlier tumbling more than 7 percent, prompting some investors to doubt the technology behind the vaccine.
See All Other NEWS in our Database.
